Summary The binding and biological activity of human TNFm on endothelial and tumour cells has been studied in the presence of monoclonal antibodies (MAbs). In Tumour necrosis factor (TNFC,) is a product of activated macrophages in response to infection and during malignancy. Systemic administration of this cytokine results in haemorrhagic necrosis of tumours in vivo Green et al., 1977) whereas in vitro, it has cytostatic and cytolytic activity on tumour cells (Helson et al., 1975) . In addition to its 'host-protective' effects, TNF, has been implicated as the causative agent in the pathology associated with septicemia, cachexia, cerebral malaria and cancer. Although recombinant TNF,,, has been used therapeutically in cancer patients, side-effects such as coagulopathy, thrombocytopaenia, lymphcytopaenia, hepatotoxicity and renal impairment have limited its application (Creaven et al., 1987; Kimura et al., 1987; Selby et al., 1987; Naworth & Stern, 1986). The systemic toxicity associated with the administration of TNFC, is believed to be, at least in part, a consequence of its interaction with the endothelium (Bevilacqua et al., 1986; Nawroth & Stern, 1986; Selby et al., 1987) . Furthermore, reducing the ability of TNFC, to bind to endothelial cells whilst preserving its tumour cytotoxic activity may have a beneficial outcome in the use of this cytokine therapeutically. We describe here a monoclonal antibody to human TNFCt which significantly enhances the tumour regression activity of the cytokine (5-10-fold) whilst inhibiting some of the associated toxic side-effects. In particular, the antibody has been shown to inhibit the procoagulant activity of TNF, on endothelial cells whilst having no effect on the binding of the cytokine to WEHI-164 tumour cells. These observations may provide the basis for an improved approach to therapy with this cytokine.
Tumour necrosis factor (TNFC,) is a product of activated macrophages in response to infection and during malignancy. Systemic administration of this cytokine results in haemorrhagic necrosis of tumours in vivo Green et al., 1977) whereas in vitro, it has cytostatic and cytolytic activity on tumour cells (Helson et al., 1975) . In addition to its 'host-protective' effects, TNF, has been implicated as the causative agent in the pathology associated with septicemia, cachexia, cerebral malaria and cancer. Although recombinant TNF,,, has been used therapeutically in cancer patients, side-effects such as coagulopathy, thrombocytopaenia, lymphcytopaenia, hepatotoxicity and renal impairment have limited its application (Creaven et al., 1987; Kimura et al., 1987; Selby et al., 1987; Naworth & Stern, 1986) . The systemic toxicity associated with the administration of TNFC, is believed to be, at least in part, a consequence of its interaction with the endothelium (Bevilacqua et al., 1986; Nawroth & Stern, 1986; Selby et al., 1987) . Furthermore, reducing the ability of TNFC, to bind to endothelial cells whilst preserving its tumour cytotoxic activity may have a beneficial outcome in the use of this cytokine therapeutically. We describe here a monoclonal antibody to human TNFCt which significantly enhances the tumour regression activity of the cytokine (5-10-fold) whilst inhibiting some of the associated toxic side-effects. In particular, the antibody has been shown to inhibit the procoagulant activity of TNF, on endothelial cells whilst having no effect on the binding of the cytokine to WEHI-164 tumour cells. These observations may provide the basis for an improved approach to therapy with this cytokine.
Materials and methods

Animals and tumour cell lines
All experiments were performed using female BALB/c mice aged [10] [11] [12] (Rathjen et al., 1991 fold dilutions commencing 1/10 to I/10 of ascitic globulin) and '251-TNF (50,000 c.p.m.) labelled using the lactoperoxidase method as previously described (Aston et al., 1985) for 3 h at 37C in a shaking water bath (WEHI-164 cells) or 1 h at 37°C in a humidified CO2 incubator (endothelial cells). At the completion of the incubation 1 ml of HBSS/BSA was added to the WEHI-164 cells, the cells spun and the bound 1251I in the cell pellet counted. For the endothelial cell assay, 1 ml of growth medium was added to each well and aspirated followed by the addition of 0.1 ml of 0.1 M sodium hydroxide to lyse the cells. The cell lysate was then transferred to tubes for counting of bound 1251I-TNF. Binding that could not be displace by an excess (1 pg) of unlabelled TNF was considered to be non-specific. Specific binding was calculated from total binding minus non-specific binding of triplicate assay tubes. One hundred per cent specific binding corresponded to 1,500 c.p.m.
Endothelial cell clotting assays Endothelial cell procoagulant activity (PCA) induction by TNF<, was determined using bovine aortic endothelial cells (BAE) according to the procedure of Bevilacqua et al. (1986) with the following modifications: BAE cells were propagated in McCoys 5A medium supplemented with 10% FCS, penicillin, streptomycin and L-gutamine in standard tissue culture flasks and 24-well dishes. TNF<,, treatment of cultures (3 fig ml-') was for 4 h at 37°C in the presence of growth medium after which the cells were washed and scrape-harvested before being frozen, thawed and sonicated. Total cellular PCA was determined in a standard one-stage clotting assay using normal donor platelet poor plasma to which 100 gl of CaCl2 and 100 gLl of cell lysate was added. The time taken for clotting to occur was then measured. Statistical significance was determined by unpaired t-test.
Preparation of FAb' monoclonal antibody fragments Univalent antibody fragments were prepared by digestion of MAb 32 with agarose immobilised papain (Pierce) according to the manufacturer's instructions. FAb' and Fc antibody fragments were separated by protein A-Sepharose affinity chromatography (Pharmacia) and tested for size and binding teristics of TNFa-MAb 32 complexes to tumour cell and endothelial cell receptors indicates that the specificity of these respective binding sites may be different. Indeed, the existence of more than one TNF, receptor has recently been documented (Hohman et al., 1989; Brockhaus et al., 1990 ).
The selectivity of MAb 32 in inhibiting the binding of TNF., to endothelial cells but not to tumour cells was confirmed by the demonstration that similar effects were observed in the corresponding bioassays with these cells in culture. Unlike MAb 32, the inhibitory antibody MAb 47 effectively blocked both the cytotoxicity of TNF, on tumour cells and the ability of the cytokine to induce procoagulant in endothelial cell cultures.
The actions of TNF., on cultured endothelial cells include activation of the pathways leading to the de novo induction of cell surface tissue factor and the loss of cell surface thrombomodulin (Nawroth & Stern, 1986) . The possible in vivo consequences of these effects include the generation of thrombin and initiation of coagulation as well as decreases in activated protein C anti-coagulant activity. The recent demonstration that anti-tissue factor antibodies or protein C administration can abrogate some of the in vivo biological activities of TNF<, (toxic shock) lends support to this view (Nawroth & Stern, 1986; Taylor et al., 1987; Edgington et al., 1989) . In contrast to the effects of MAb 32 on TNF, activity in WEHI-164 cells, the antibody has been shown to be significantly more inhibitory than MAb 47 on the induction of procoagulant activity in cultured endothelial cells. The greater inhibitory potency of MAb 32 in the procoagulant assay, as compared with MAb 47 in receptor binding, is still unclear; however, it has been shown (Brett et al., 1989) that endothelial cells may have more than one class of TNF<,, receptor, of which the functionally representative one is reflected in the bioassay rather than in the radioreceptor assay (see below).
Predictably, the systemic administration of TNFa-MAb 32 complex would be anticipated to result in selective enhancement of the tumour regressive activity to the cytokine and possibly in inhibition of its effects on the endothelium. Here it has been shown that the pre-complexing of TNF. with
MAb 32 results in a significant (up to 10-fold) enhancement of the tumour regressive activity of the cytokine with no apparent concommitant increase in TNF toxicity. In contrast, other antibody specificities (inhibitory or otherwise) failed to produce this unique effect. The ability of univalent FAb' fragments, derived from MAb 32, to also enhance the cytotoxicity of TNF, in this fashion indicates that the enhancement phenomenon is independent of antibody bivalency or Fc-region mediated effects (Aston et al., 1989 Aston et al., 1989) . The potential benefits to the patient of circulating autoantibody to cytokines, particularly in relation to the latter mechanism, have also been discussed recently (Bendtzen et al., 1990) . It has been proposed in these studies that cytokine autoantibody occurs with high frequency in patients on cytokine therapy and may, in cases, benefit the patient by acting as a specific 'carrier' molecule. The recent identification of a natural TNFCt binding protein (Engelmann et al., 1989) , which may have regulatory effects on the cytokine in vivo and the existence of at least two structurally distinct receptors (Hohman et al., 1989; Engelmann et al., 1989; Loetscher et al., 1990; Espevik et al., 1990) , would also lend support to the above hypothesis. Endothelial cells appear to express two TNF receptors which mediate different biological effects of TNF (Brett et al., 1989 ). It appears that expression of tissue factor in response to TNF is signalled by a non-G protein linked receptor while increased vascular permeability in response to TNF occurs via a G protein-linked receptor. More recent evidence (Tartaglia et al., 1991) has further indicated that the two TNF receptors initiate distinct signalling pathways that result in the induction of different cellular responses namely thymocyte proliferation and LM cytotoxicity. The antibody described here may not only enable further clinical trials with TNF< but may have application in cancers where circulating TNFa levels are high and evidence of coagulopathy is apparent.
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